Rosucol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rosucol

Property Description
Active ingredient Rosuvastatin
Form Film-coated tablet
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Managing elevated lipid levels (e.g., high cholesterol)
Origin Synthetic compound

Rosucol is a prescription-only medication specifically used for managing elevated lipid levels in the bloodstream, such as high cholesterol. The drug is classified within the statin family of medicines, which are clinically recognized as foundational agents for addressing conditions like hypercholesterolemia and dyslipidemia. Understanding its classification and composition is crucial for defining its therapeutic role.


What Type of Medicine is Rosucol?

Rosucol is categorized as an HMG-CoA reductase inhibitor, a class of synthetic drugs known for their powerful lipid-lowering capabilities. The active substance in Rosucol is Rosuvastatin, which is synthesized to selectively interfere with cholesterol production within the liver. This classification immediately identifies the product as a highly specific agent dedicated to regulating the balance of fats in the blood. Rosuvastatin is recognized among the statins for its pronounced potency, a characteristic widely supported by pharmacological studies.


Composition and Physical Form of Rosucol

The medicine is a single active ingredient product, deriving its therapeutic effect solely from Rosuvastatin calcium. Rosucol is manufactured as a film-coated tablet intended for the oral route of administration. The tablet formulation simplifies ingestion and ensures a consistent delivery of the synthetic compound to the body. This pharmaceutical form, along with various pharmaceutical excipients that provide structure and stability, is the standard presentation for this hypolipidemic agent.


What is the General Purpose of Rosucol?

The general purpose of Rosucol is to help control the excess levels of fats in the blood, particularly harmful low-density lipoprotein cholesterol (LDL-C). The underlying mechanism is a dual action: Rosuvastatin works to slow the body’s internal cholesterol production while simultaneously increasing the liver's capacity to remove existing cholesterol from the blood. By facilitating this efficient reduction and clearance of fats, Rosucol serves the critical general purpose of maintaining a healthier lipid profile, which is fundamental to cardiovascular support in patients with confirmed high cholesterol levels.

What side effects are possible with Rosucol?

Possible Side Effects and Safety Information

The safety profile of Rosucol (Rosuvastatin) is formally defined by regulatory agencies, classifying potential adverse reactions by frequency and the body system affected. All safety information is based strictly on documentation from government health authorities.


Documented Adverse Reactions

The most frequently reported adverse reactions are classified as Common (ge 1/100 to < 1/10 users) in regulatory documents and include myalgia (muscle pain), headache, constipation, nausea, and abdominal pain. Certain effects are classified as Rare (ge 1/10,000 to < 1/1,000 users), such as pancreatitis, myopathy, and rhabdomyolysis. The development of new-onset diabetes mellitus is documented as a class effect and is classified as common.

Adverse reactions are grouped into System-Organ Classes (SOCs), with key effects noted in Musculoskeletal (e.g., rhabdomyolysis, myopathy), Hepatobiliary (e.g., hepatitis, jaundice), and Nervous System disorders.


Serious Safety Considerations and Limitations

Regulatory labeling highlights serious adverse reactions including Rhabdomyolysis (severe muscle breakdown) and rare reports of hepatic failure. Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome are also documented.

Population-specific safety considerations are formally stated: Rosucol is contraindicated in patients with active liver disease and in those with severe renal impairment due to increased systemic exposure. Increased systemic exposure has also been documented in Asian patients compared to Caucasians. The medicine is formally contraindicated during pregnancy and breastfeeding. The official labeling states that Creatine Kinase (CK) monitoring should be considered before starting treatment for patients with pre-disposing factors for myopathy.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory documentation does not list a specific symptom profile or cluster for acute overdose of Rosucol (rosuvastatin); clinical experience is based instead on severe adverse reactions and exposure to high doses. The primary regulatory concern remains the potential for severe, life-threatening systemic outcomes. Documented severe outcomes include rhabdomyolysis (severe muscle breakdown) and subsequent acute renal failure due to myoglobinuria. Rare, serious cases of hepatic failure have also been reported in association with high exposure. Laboratory findings that require prompt attention include markedly elevated Creatine Kinase (CK) levels, which serve as a marker for severe muscle injury.

Emergency Actions and Required Help

If an overdose of Rosucol is suspected, regulatory guidance is explicit: individuals must seek immediate medical attention and call a doctor or go to the nearest hospital emergency room right away. The official treatment for over-ingestion is strictly symptomatic and supportive, as no specific antidote is known for rosuvastatin according to prescribing information. Because the active ingredient is highly bound to plasma proteins, procedures such as haemodialysis are not expected to be effective in aiding clearance from the body. Management requires continuous hospital monitoring, including monitoring of liver enzymes, and temporary discontinuation of the medication if conditions posing a high risk for severe injury are present.

Therapeutic Uses of Rosucol

What Rosucol Treats: Main Uses and Benefits

Rosucol is primarily applied across domains where additional symptomatic support is needed in contexts involving elevated lipid levels. The application is commonly used when short-term symptomatic assistance is appropriate for conditions presenting with acute or episodic manifestations. The medicine is relevant in contexts involving heightened systemic burden and contributes to easing the overall symptom load, particularly during periods of heightened symptoms where patients experience increased discomfort or tension.

Rosucol assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations, providing supportive relief when symptoms interfere with routine activities. It is applied in addressing symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes.

Quick Fact: Supports functional stability during symptomatic phases

Regulatory References

  1. Product Monograph for Rosuvastatin

Eligibility and Restrictions for Use

The eligibility for Rosucol (Rosuvastatin) is strictly defined by regulatory authorities based on age, organ function, and physiological status. The medicine is intended for use in adults and in pediatric patients with specific types of Familial Hypercholesterolemia, starting from seven or eight years of age, depending on the condition. Safety and effectiveness are not established for general pediatric hyperlipidemia.

Contraindications

Use of Rosucol is absolutely contraindicated in several population groups:

  • Patients with active liver disease or unexplained persistent elevations of hepatic transaminases.
  • Women who are pregnant or who may become pregnant, and nursing mothers.
  • Individuals with a known hypersensitivity to the drug or its components.

Restrictions and Limitations

Specific restrictions apply to patients with certain risk factors:

  • Severe Renal Impairment (Creatinine Clearance <30 mL/min): Use is either contraindicated (EMA) or severely restricted to a maximum dose of 10 mg (FDA).
  • Myopathy Risk Factors: The mathbf40 mg dose is contraindicated in patients with predisposing factors for myopathy, such as uncontrolled hypothyroidism, or being of Asian descent.
  • Asian Descent: Use is permitted but requires consideration of a lower starting dose due to increased systemic exposure.

What should I know about interactions with other medicines?

Rosucol (Rosuvastatin) has documented interactions with other medicines and products that are managed through mandatory restrictions, dose limitations, or administration timing requirements, as defined in regulatory labeling.

Exposure-Altering Interactions

The most clinically significant interactions are driven by interference with drug transport proteins, specifically OATP1B1 and BCRP. Inhibition of these transporters leads to an increase in rosuvastatin systemic exposure.

  • Co-administration with Cyclosporine requires the Rosucol dose to be limited to a maximum of 5 mg once daily.
  • Combination with Gemfibrozil should be avoided, and if necessary, the dose must not exceed 10 mg.
  • Specific Protease Inhibitors also necessitate a dose limit of 10 mg due to the exposure increase.

Pharmacodynamic Risk and Timing

Rosucol co-administration with other fibrates or lipid-modifying doses of Niacin (ge 1 g/day) amplifies the documented risk of skeletal muscle effects (myopathy). Combining Rosucol with Warfarin requires close monitoring of the International Normalized Ratio (INR) as it may be prolonged.

Mandatory administration rules require Rosucol to be separated from Aluminum and Magnesium Hydroxide Antacids by at least 2 hours to ensure proper absorption. Cautions regarding heightened systemic exposure and myopathy risk are specifically documented for Asian patients and patients with moderate renal impairment. Additionally, the use of Rosucol with substantial quantities of alcohol may increase the documented risk of liver damage.

Mechanism of Action

The mechanism of Rosucol centers on two primary actions within the liver: blocking intrinsic synthesis and enhancing particle clearance. Rosucol acts as a competitive inhibitor of the enzyme HMG-CoA reductase, which catalyzes a crucial, rate-limiting step in the mevalonate pathway of cholesterol synthesis. This molecular interaction reduces the liver cell's capacity for producing cholesterol.

The resulting reduction in intracellular cholesterol initiates a compensatory cellular response: the up-regulation of Low-Density Lipoprotein (LDL) receptors on the hepatocyte surface. This increase in receptor expression enhances the cell's capacity to capture and remove circulating LDL particles from the blood plasma, consequently lowering the plasma concentration of these particles. Beyond lipid metabolism, the drug also influences non-lipid pathways (pleiotropic effects), which involve the modulation of localized inflammatory processes and the function of the endothelium within the vessel walls.

Dosage and Administration Information

How Rosucol is Used: Official Administration Guidelines

Rosucol (rosuvastatin) is formulated as a film-coated tablet intended exclusively for the oral route of administration. The tablet is taken as a single dose once daily and can be administered with or without food at any time of day. The proper usage protocol is defined by specific dosage rules, timing constraints, and special population limits.


Standard Dosing and Schedule

The usual adult starting dose is typically 10 mg or 20 mg once daily. Dosing ranges from 5 mg up to the maximum of 40 mg daily. Dosage adjustments, if necessary, should only be considered after a minimum interval of two to four weeks has passed since initiating therapy or titrating the dose, allowing for assessment of response.


Administration Requirements and Limits

Guideline Official Instruction
Tablet Integrity The film-coated tablet must be swallowed whole.
Antacid Timing Rosuvastatin should be taken at least 2 hours before antacids containing aluminum and magnesium hydroxide.
Missed Dose Do not take an extra dose to make up for a missed dose; resume treatment with the next scheduled intake.

Population-Specific Dose Restrictions

Specific limitations exist for certain groups. For patients with severe renal impairment (not on hemodialysis), the maximum daily dose is 10 mg once daily, and the starting dose is limited to 5 mg. Similarly, for patients of Asian descent, therapy is initiated at the lower 5 mg once daily starting dose. These limits ensure the medicine is used within established parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rosucol (Rosuvastatin)

Evidence for Managing High Cholesterol and Mixed Lipids

Research for Rosucol has been conducted primarily through large-scale, short-to-intermediate-term Randomized Controlled Trials (RCTs). These studies explored patterns related to blood fat measurements in adults with high cholesterol (hypercholesterolemia) and mixed dyslipidemia. Studies examined outcomes related to systemic imbalance, such as changes in LDL-C and total cholesterol. Studies reported measured shifts in these blood lipid levels, with the greatest measured changes often reported for LDL-C. Research provides insight into short-term changes in these blood markers over the study period. However, the full relationship between these short-term lipid changes and long-term clinical event outcomes remains to be established by this specific body of evidence alone.


Studies on Preventing First Cardiovascular Events

Dedicated, long-term clinical trials have been conducted to explore the use of the drug in specific, high-risk people who had not yet experienced a heart attack or stroke. These studies monitored time until the occurrence of a composite major cardiovascular event (such as a nonfatal heart attack or stroke). One landmark trial explored whether Rosuvastatin use corresponded with differences in the incidence of composite cardiovascular events over the study period compared to the control group.


Research in Patients with Established Heart Disease

This research area explores the use of the drug in adults with established heart conditions, such as Coronary Artery Disease (CAD). Studies monitored the future incidence of Major Adverse Cardiac and Cerebrovascular Events (MACE). Research highlights that for patients with established disease, intensive LDL-C lowering, which was studied in research related to this drug, was associated with differences in the observed incidence of MACE. Imaging research describes that measurements of atherosclerotic plaque volume taken during the study period were associated with Rosuvastatin’s use.


What Scientific Research Gaps Remain

Scientific research gaps exist where data are still emerging or where evidence is limited: Comparative evidence is lacking from large-scale, head-to-head RCTs against all high-intensity statins for long-term clinical endpoints. Data for certain groups remain insufficient, particularly for long-term event outcomes in younger patients and in specific ethnic cohorts. The full relationship to long-term prevention of adult cardiovascular events in children with Familial Hypercholesterolemia is not fully established.

Key Studies & References

  1. Rosuvastatin calcium (Rosucol) Product Monograph (Health Canada)
  2. NICE Guideline: Cardiovascular disease: risk assessment and reduction, including lipid modification

Frequently Asked Questions (FAQ)

Common questions about Rosucol (FAQ)

Q: Does taking Rosucol mean I can stop following a low-cholesterol diet?

A: According to official product information, Rosucol (rosuvastatin) is indicated as an adjunct to diet. This emphasizes that the medication is intended to complement dietary changes.

Regulatory guidelines state that a cholesterol-lowering diet should be established before and maintained throughout Rosucol treatment.


Q: Does Rosucol help with raising the 'good' cholesterol (HDL)?

A: Official regulatory documents indicate that Rosucol is indicated for reducing several elevated lipid types, including LDL-cholesterol, and for increasing HDL-cholesterol (often called the 'good' cholesterol).

This benefit applies to patients diagnosed with primary hyperlipidemia and mixed dyslipidemia.


Q: Do statins like Rosucol have an anti-inflammatory effect in the body?

A: Studies and official information indicate that Rosucol, like other statins, has effects that go beyond just lowering lipids, which are described as pleiotropic effects.

These documented effects include the modulation of localized inflammatory processes and influences on the function of blood vessel linings (endothelium).


Q: Does Rosucol interact with any common herbal supplements like St. John's Wort?

A: Official patient counseling information emphasizes the importance of informing the healthcare provider about all substances used. This includes any prescription or over-the-counter medicines, vitamins, and all herbal products or supplements.

This disclosure is important because other supplements or medicines can sometimes alter the level of rosuvastatin in the blood.


Q: Why is Rosucol taken once a day, and does the time of day matter?

A: Regulatory information specifies that Rosucol is administered as a single dose once daily. The drug's official labeling allows for this once-daily regimen.

Rosucol can be taken at any time of day, and you may take it either with or without food.


Q: Why do some patients report joint pain or stiffness while on Rosucol?

A: Joint pain, formally known as arthralgia, is listed in official adverse reaction data as a commonly reported effect in clinical studies with Rosucol (rosuvastatin).

Joint pain, stiffness, or any unexpected muscular symptoms should be brought to the attention of the prescribing healthcare professional.


Q: How is Rosucol primarily eliminated from the body (urine vs. feces)?

A: According to pharmacokinetic data referenced in regulatory documents, the majority of the Rosucol dose (approximately 90%) is eliminated unchanged through the feces.

A smaller portion of the drug is eliminated through the urine.


Q: Are there any withdrawal symptoms if I stop taking Rosucol suddenly?

A: Regulatory guidance indicates that patients should not stop taking statin therapy suddenly without consulting their healthcare provider.

While official labels do not explicitly list 'withdrawal symptoms,' discontinuing the medication without guidance may increase the underlying cardiovascular risk that the drug is managing.


Q: Can Rosucol help slow down the buildup of plaque in the arteries?

A: Official labeling indicates that Rosucol is indicated, along with an appropriate diet, to slow the progression of atherosclerosis.

Atherosclerosis is the condition involving plaque buildup in the arteries. This indication is part of a treatment strategy to lower cholesterol to target levels.


Q: Does taking Rosucol with food change how the medicine is absorbed?

A: Official administration guidelines state that Rosucol (rosuvastatin) can be taken with or without food.

This administration flexibility simplifies the daily regimen for patients.


Q: How often are follow-up blood tests usually required after starting Rosucol?

A: Official labeling states that lipid levels should be analyzed as early as two to four weeks after starting Rosucol or adjusting the dose to assess response.

Additionally, liver enzyme tests are typically performed before initiating therapy and as clinically indicated thereafter, as determined by the healthcare provider.


Q: Can I still safely drive a car or operate machinery while taking Rosucol?

A: Rosucol has negligible influence on the ability to drive or use machines. However, patients should be aware of potential adverse reactions.

Patients should be aware that if they experience side effects like dizziness or headache, these symptoms may affect their ability to safely drive or operate complex machinery.


Q: Can Rosucol be used for children and teenagers with inherited high cholesterol?

A: Rosucol is indicated for specific, inherited forms of high cholesterol in pediatric patients, such as familial hypercholesterolemia (both heterozygous and homozygous forms).

Specific eligibility criteria, including age ranges, apply for these indications as outlined in the official prescribing information.


Q: Are there any conditions where the 40 mg dose of Rosucol is considered too high or unsafe?

A: The maximum dose of 40 mg is contraindicated (not recommended for use) in certain patients with predisposing factors for muscle toxicity (myopathy).

These factors include having uncontrolled hypothyroidism, being of Asian descent, or taking certain medicines that interact with Rosucol, as detailed in the official prescribing information.


Q: Is it normal to feel unusually tired or weak when starting Rosucol?

A: Weakness (known as asthenia) is listed in official adverse reaction data as a commonly reported effect in clinical studies.

Any unusual tiredness, weakness, or muscle symptoms should be brought to the attention of a healthcare professional.

How should Rosucol be stored and disposed of?

How to Store and Dispose of Rosucol?

To maintain the stability and effectiveness of Rosucol (rosuvastatin) tablets, they must be stored at controlled room temperature, typically defined as below 30 C (86 F). The medication must be protected from light and moisture, meaning it should remain in its original container or blister packaging until the time of use. Do not use the tablets past the expiration date printed on the packaging.

For safety, all medication must be stored out of the sight and reach of children.

Proper disposal is essential to protect the environment. Do not dispose of Rosucol via household waste or by flushing it down the toilet or sink. Unused or expired medication should be returned to a pharmacist or local waste disposal service, following official guidelines for the environmentally safe disposal of medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rosucol found in:

A-Z Index: